Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments

被引：1

作者：

Cancanelli, Luca ^{[1
]}

Rivano, Melania ^{[2
]}

Di Spazio, Lorenzo ^{[3
]}

Chiumente, Marco ^{[4
]}

Mengato, Daniele ^{[5
]}

Messori, Andrea ^{[6
]}

机构：

[1] Azienda Ulss 2 Marca Trevigiana, Hosp Pharm Dept, I-31033 Castelfranco Veneto, Treviso, Italy

[2] Binaghi Hosp, Hosp Pharm Dept, I-09126 Cagliari, Italy

[3] Santa Chiara Hosp, Hosp Pharm Dept, I-38122 Trento, Italy

[4] Soc Italiana Farm Clin & Terapia SIFaCT, Sci Direct, I-20159 Milan, Italy

[5] Univ Padua, Hosp Pharm Dept, Azienda Osped, I-35122 Padua, Italy

[6] Reg Hlth Serv, HTA Unit, I-50136 Florence, Italy

来源：

HEMATOLOGY REPORTS | 2023年 / 15卷 / 01期

关键词：

relapsed-refractory multiple myeloma; overall survival; CAR-T; non-CAR-T agents; OPEN-LABEL; DEXAMETHASONE; OUTCOMES;

D O I：

10.3390/hematolrep15010006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In recent years, new treatments have been studied for relapsed-refractory multiple myeloma (RRMM), including two CAR-T products and a variety of non-CAR-T agents. Since direct comparisons between these innovative treatments are not available, indirect comparisons can be of interest. Reconstruction of individual patient data from Kaplan-Meier graphs (e.g., according to the Shiny method) has been the subject of numerous reports that have fully validated their performance. In the present systematic review, we evaluated six treatments proposed for RRMM, including two CAR-T products (ciltacabtagene autoleucel and idecabtagene vicleucel) and four treatments not based on a CAR-T (melflufen plus dexamethasone, isatuximab plus dexamethasone, selinexor, and belantamab). The endpoint was overall survival (OS). Our results showed statistically significant differences in OS across these treatments. In particular, ciltacabtagene autoleucel showed better OS than idecabtagene vicleucel. As regards non-CAR-T treatments, the ranking in OS was headed by isatuximab plus dexamethasone, followed by belantamab, selinexor, and melflufen plus dexamethasone. In conclusion, while the Shiny method has confirmed its validity in reconstructing individual patient data, our indirect comparisons have offered some original clues to interpret the results of OS published in these studies.

引用

页码：57 / 65

页数：9

共 20 条

[1]

[Anonymous], 2021, ANKIT ROHATGI WEBPLO

[2] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].

Berdeja, Jesus G. ;

Madduri, Deepu ;

Usmani, Saad Z. ;

Jakubowiak, Andrzej ;

Agha, Mounzer ;

Cohen, Adam D. ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Htut, Myo ;

Lesokhin, Alexander ;

Deol, Abhinav ;

Munshi, Nikhil C. ;

O'Donnell, Elizabeth ;

Avigan, David ;

Singh, Indrajeet ;

Zudaire, Enrique ;

Yeh, Tzu-Min ;

Allred, Alicia J. ;

Olyslager, Yunsi ;

Banerjee, Arnob ;

Jackson, Carolyn C. ;

Goldberg, Jenna D. ;

Schecter, Jordan M. ;

Deraedt, William ;

Zhuang, Sen Hong ;

Infante, Jeffrey ;

Geng, Dong ;

Wu, Xiaoling ;

Carrasco-Alfonso, Marlene J. ;

Akram, Muhammad ;

Hossain, Farah ;

Rizvi, Syed ;

Fan, Frank ;

Lin, Yi ;

Martin, Thomas ;

Jagannath, Sundar .

LANCET, 2021, 398 (10297) :314-324

[3] Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials [J].

Cancanelli, Luca ;

Rivano, Melania ;

Di Spazio, Lorenzo ;

Chiumente, Marco ;

Mengato, Daniele ;

Messori, Andrea .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)

[4] Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma [J].

Chari, Ajai ;

Vogl, Dan T. ;

Gavriatopoulou, Maria ;

Nooka, Ajay K. ;

Yee, Andrew J. ;

Huff, Carol A. ;

Moreau, Philippe ;

Dingli, David ;

Cole, Craig ;

Lonial, Sagar ;

Dimopoulos, Meletios ;

Stewart, A. Keith ;

Richter, Joshua ;

Vij, Ravi ;

Tuchman, Sascha ;

Raab, Marc S. ;

Weisel, Katja C. ;

Delforge, Michel ;

Cornell, Robert F. ;

Kaminetzky, David ;

Hoffman, James E. ;

Costa, Luciano J. ;

Parker, Terri L. ;

Levy, Moshe ;

Schreder, Martin ;

Meuleman, Nathalie ;

Frenzel, Laurent ;

Mohty, Mohamad ;

Choquet, Sylvain ;

Schiller, Gary ;

Comenzo, Raymond L. ;

Engelhardt, Monika ;

Illmer, Thomas ;

Vlummens, Philip ;

Doyen, Chantal ;

Facon, Thierry ;

Karlin, Lionel ;

Perrot, Aurore ;

Podar, Klaus ;

Kauffman, Michael G. ;

Shacham, Sharon ;

Li, Lingling ;

Tang, Shijie ;

Picklesimer, Carla ;

Saint-Martin, Jean-Richard ;

Crochiere, Marsha ;

Chang, Hua ;

Parekh, Samir ;

Landesman, Yosef ;

Shah, Jatin .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (08) :727-738

[5]

Di Spazio Lorenzo, 2022, Cureus, V14, pe21065, DOI 10.7759/cureus.21065

[6] Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma [J].

Dimopoulos, Meletios ;

Bringhen, Sara ;

Anttila, Pekka ;

Capra, Marcelo ;

Cavo, Michele ;

Cole, Craig ;

Gasparetto, Cristina ;

Hungria, Vania ;

Jenner, Matthew ;

Vorobyev, Vladimir ;

Ruiz, Eduardo Yanez ;

Yin, Jian Y. ;

Saleem, Rao ;

Hellet, Maeva ;

Mace, Sandrine ;

Paiva, Bruno ;

Vij, Ravi .

BLOOD, 2021, 137 (09) :1154-1165

[7] CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status [J].

Du, Juan ;

Wei, Runhong ;

Jiang, Songfu ;

Jiang, Hua ;

Li, Lu ;

Qiang, Wanting ;

He, Haiyan ;

Shi, Lin ;

Ma, Qiuling ;

Yu, Kang ;

Zhang, Xiaoyuan ;

Ding, Hanyi ;

Sun, Xuedong ;

Xiang, Fang ;

Zhu, Lin ;

Cheng, Zhi ;

Fu, Weijun .

AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (07) :933-941

[8] Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy [J].

Gandhi, Ujjawal H. ;

Cornell, Robert F. ;

Lakshman, Arjun ;

Gahvari, Zhubin J. ;

McGehee, Elizabeth ;

Jagosky, Megan H. ;

Gupta, Ridhi ;

Varnado, William ;

Fiala, Mark A. ;

Chhabra, Saurabh ;

Malek, Ehsan ;

Mansour, Joshua ;

Paul, Barry ;

Barnstead, Alyssa ;

Kodali, Saranya ;

Neppalli, Amarendra ;

Liedtke, Michaela ;

Narayana, Swapna ;

Godby, Kelly N. ;

Kang, Yubin ;

Kansagra, Ankit ;

Umyarova, Elvira ;

Scott, Emma C. ;

Hari, Parameswaran ;

Vij, Ravi ;

Usmani, Saad Z. ;

Callander, Natalie S. ;

Kumar, Shaji K. ;

Costa, Luciano J. .

LEUKEMIA, 2019, 33 (09) :2266-2275

[9]

Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]

[10] IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves [J].

Liu, Na ;

Zhou, Yanhong ;

Lee, J. Jack .

BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)

← 1 2 →